Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1146978 | 1.00 | ALDH1A1 (0.52) | ALDH1A1MAPTPTGS1SLC1A3SLC1A2 | |
| SCHEMBL18653125 | 0.80 | ALDH1A1 (0.36) | ALDH1A1MAPTPTGS1SLC1A3SLC1A2 | |
| SCHEMBL1952232 | 0.75 | KMT2A (0.39) | ALDH1A1MAPTPTGS1 | |
| SCHEMBL1952233 | 0.75 | KMT2A (0.39) | ALDH1A1MAPTPTGS1 | |
| SCHEMBL25211968 | 0.74 | ALDH1A1 (0.33) | ALDH1A1MAPTPTGS1SLC1A3SLC1A2 | |
| SCHEMBL28819982 | 0.73 | ALDH1A1 (0.44) | ALDH1A1MAPTPTGS1SLC1A3SLC1A2 | |
| SCHEMBL7277575 | 0.73 | ALDH1A1 (0.45) | ALDH1A1MAPTPTGS1SLC1A3SLC1A2 | |
| Hydrochloric Acid SCHEMBL14780395 | 0.73 | DPP4 (0.34) | ALDH1A1MAPTPTGS1 | |
| SCHEMBL7277580 | 0.73 | ALDH1A1 (0.45) | ALDH1A1MAPTPTGS1SLC1A3SLC1A2 | |
| SCHEMBL6433 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167507-B1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2016-03-02 | — | — | EP | claimed |
| US-20120220602-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2012-08-30 | — | — | US | claimed |
| US-20110105524-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2011-05-05 | — | — | US | claimed |
| EP-2167507-A1 | CYSTEINE PROTEASE INHIBITORS | Medivir AB (SE) | 2010-03-31 | — | — | EP | claimed |
| US-20090023748-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | claimed |
| WO-2009000877-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-12-31 | — | — | WO | claimed |
| WO-2008114054-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-09-25 | — | — | WO | claimed |
| EP-1907503-A1 | CORROSION INHIBITOR OR INTENSIFIER FOR USE IN ACIDIZING TREATMENT FLUIDS | Halliburton Energy Services, Inc. (US) | 2008-04-09 | — | — | EP | claimed |
| WO-2007007025-A1 | CORROSION INHIBITOR OR INTENSIFIER FOR USE IN ACIDIZING TREATMENT FLUIDS | HALLIBURTON ENERGY SERVICES, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| US-20070010404-A1 | Corrosion inhibitor or intensifier for use in acidizing treatment fluids | HALLIBURTON ENERGY SERVICES, INC. | 2007-01-11 | — | — | US | claimed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | claimed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | claimed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | claimed |
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724459-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Peptidream Inc (JP) | 2026-04-15 | — | — | EP | disclosed |
| US-20260022102-A1 | 1,2,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators | AURIGENE ONCOLOGY LIMITED (IN) | 2026-01-22 | — | — | US | disclosed |
| WO-1999011608-A1 | MALONIC ACID BASED MATRIX METALLOPROTEINASE INHIBITORS | ROCHE DIAGNOSTICS GMBH (DE) | 1999-03-11 | — | — | WO | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105524-A1 | CYSTEINE PROTEASE INHIBITORS | CTSK, CTSL, CTSV | ALDH1A1 3386/4885MAPT 4249/4885PTGS1 1183/4885 |
| US-20090023748-A1 | Cysteine Protease Inhibitors | CTSK, CTSL, CTSV | ALDH1A1 3386/4885MAPT 4249/4885PTGS1 1183/4885 |
| US-20120220602-A1 | CYSTEINE PROTEASE INHIBITORS | CTSK, CTSL, CTSV | ALDH1A1 3386/4885MAPT 4249/4885PTGS1 1183/4885 |
| US-20260022102-A1 | 1,2,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators | CD274, PDCD1, PDCD1LG2 | ALDH1A1 253/4885MAPT 4477/4885PTGS1 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.